E. Villa et al., Natural history of inoperable hepatocellular carcinoma: Estrogen receptors' status in the tumor is the strongest prognostic factor for survival, HEPATOLOGY, 32(2), 2000, pp. 233-238
Clinical course in hepatocellular carcinoma may be very different. We prosp
ectively evaluated 96 patients with hepatocellular carcinoma unsuitable For
radical therapy to investigate Factors that could influence survival. Clin
ical, pathologic, and molecular data of patients were analyzed by univariat
e and multivariate analysis. The overall actuarial probability of survival
at year 1, 2, 3, 4, 5, and 6 was 72%, 41%, 38%, 24%, 20%, and 9%. At univar
iate analysis, alphafetoprotein (AFP) (P = .0082); alkaline phosphatase (P
= .0281); bilirubin (P = .0076); etiology (P = .0001); increment of turner
mass at month 3 (P = .0051); type of estrogen receptor (ER) in the tumor (P
= .0000); prothrombin time (P = .0003); and portal vein thrombosis (P = .0
000) had prognostic significance. At multivariate analysis, only type of ER
(P = .0000) and bilirubin (P = .0030) showed independent predictive value
for mortality. Survival was significantly longer in patients with wild-type
estrogen receptors (P = .0000). Cumulative probability of survival at year
1, 2, 3, 4, 5, and 6 was 94%, 66%, 52%, 43%, 35%, and 18% for wild-type an
d 51%, 21%, 16%, and 9% for variant estrogen receptors (no patients alive a
fter 4 years). Hepatitis B surface antigen (HBsAg)-positive patients with v
ariant ERs had a median survival of 8 months versus 45 months in antihepati
tis C virus-positive patients with wild-type ERs (P = .0001). In conclusion
, (1) the presence of variant liver ER transcripts in the tumor was the str
ongest negative predictor of survival in inoperable hepatocellular carcinom
a; (2) their presence was associated with spontaneous survival significantl
y worse than in patients with wild-type estrogen receptors; and (3) HBsAg-p
ositive patients with variant receptors were characterized by the worst sur
vival.